Tarsus Pharmaceuticals annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals Debt-to-Equity Ratio Growth & History (TARS)
Tarsus Pharmaceuticals's debt-to-equity ratio was 0.24 for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.24 | −0.08 | −25.07% |
| 2024 | 2024-12-31 | 0.32 | 0.16 | +100.32% |
| 2023 | 2023-12-31 | 0.16 | 0.06 | +52.90% |
| 2022 | 2022-12-31 | 0.11 | 0.10 | +1371.18% |
| 2021 | 2021-12-31 | 0.01 | 0.00 | +43.04% |
| 2020 | 2020-12-31 | 0.01 | — | — |
Tarsus Pharmaceuticals quarterly debt-to-equity ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.26 | 0.04 | +17.60% |
| Q1 2026 | 2026-03-31 | 0.25 | 0.04 | +20.25% |
| Q4 2025 | 2025-12-31 | 0.24 | −0.08 | −25.07% |
| Q3 2025 | 2025-09-30 | 0.25 | −0.06 | −20.53% |
| Q2 2025 | 2025-06-30 | 0.22 | −0.07 | −25.38% |
| Q1 2025 | 2025-03-31 | 0.21 | 0.09 | +81.04% |
| Q4 2024 | 2024-12-31 | 0.32 | 0.16 | +100.32% |
| Q3 2024 | 2024-09-30 | 0.31 | 0.16 | +108.19% |
| Q2 2024 | 2024-06-30 | 0.29 | 0.11 | +60.59% |
| Q1 2024 | 2024-03-31 | 0.12 | −0.03 | −19.74% |
| Q4 2023 | 2023-12-31 | 0.16 | 0.06 | +52.90% |
| Q3 2023 | 2023-09-30 | 0.15 | 0.05 | +50.05% |
| Q2 2023 | 2023-06-30 | 0.18 | 0.09 | +99.65% |
| Q1 2023 | 2023-03-31 | 0.15 | 0.01 | +7.20% |
| Q4 2022 | 2022-12-31 | 0.11 | 0.10 | +1371.18% |
| Q3 2022 | 2022-09-30 | 0.10 | 0.09 | +1274.15% |
| Q2 2022 | 2022-06-30 | 0.09 | 0.09 | +2663.97% |
| Q1 2022 | 2022-03-31 | 0.14 | 0.13 | +3571.67% |
| Q4 2021 | 2021-12-31 | 0.01 | 0.00 | +43.04% |
| Q3 2021 | 2021-09-30 | 0.01 | — | — |
| Q2 2021 | 2021-06-30 | 0.00 | — | — |
| Q1 2021 | 2021-03-31 | 0.00 | — | — |
| Q4 2020 | 2020-12-31 | 0.01 | — | — |
Tarsus Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Tarsus Pharmaceuticals's debt-to-equity ratio increased from 0.01 to 0.24, a change of 0.24. The latest reported quarter, Q2 2026, shows 0.26.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗